Jakavi


Indications and Reactions:

Role Indications Reactions
Primary
Myelofibrosis 72.2%
Splenomegaly 3.8%
Hypertension 3.3%
Myeloproliferative Disorder 3.3%
Immunisation 2.8%
Polycythaemia Vera 1.9%
Chronic Myeloid Leukaemia 1.4%
Haemoglobin Decreased 1.4%
Benign Prostatic Hyperplasia 0.9%
Cerebrovascular Accident 0.9%
Deep Vein Thrombosis 0.9%
Dyspepsia 0.9%
Hypothyroidism 0.9%
Iron Overload 0.9%
Polycythaemia 0.9%
Skin Reaction 0.9%
Thrombocytosis 0.9%
Blast Cell Proliferation 0.5%
Blood Uric Acid Increased 0.5%
Bone Pain 0.5%
Death 15.0%
Pneumonia 10.0%
Weight Increased 8.0%
Pancytopenia 7.0%
White Blood Cell Count Increased 7.0%
Platelet Count Decreased 6.0%
Herpes Zoster 5.0%
Myelofibrosis 4.0%
Renal Failure 4.0%
Splenomegaly 4.0%
Thrombocytopenia 4.0%
Thrombocytosis 4.0%
Disease Progression 3.0%
Pulmonary Arterial Hypertension 3.0%
Sepsis 3.0%
Treatment Failure 3.0%
Urinary Tract Infection 3.0%
White Blood Cell Count Decreased 3.0%
Blast Cells Present 2.0%
Cerebrovascular Accident 2.0%
Secondary
Myelofibrosis 49.1%
Thrombocytosis 10.0%
Hypertension 9.1%
Myeloproliferative Disorder 5.9%
Haemoglobin Decreased 4.1%
Splenomegaly 3.6%
Dyspepsia 2.7%
Hypothyroidism 2.7%
Iron Overload 2.7%
Skin Reaction 2.7%
Bone Pain 1.4%
Nephrolithiasis 1.4%
Polycythaemia 0.9%
Polycythaemia Vera 0.9%
Portal Vein Thrombosis 0.9%
Blast Cell Proliferation 0.5%
Chronic Myeloid Leukaemia 0.5%
Off Label Use 0.5%
Platelet Count Decreased 0.5%
Weight Increased 13.7%
Vitiligo 10.5%
Pneumonia 8.4%
Thrombocytosis 7.4%
Renal Failure Acute 6.3%
Coronary Artery Disease 5.3%
Haemoglobin Decreased 5.3%
Wound 5.3%
Platelet Count Decreased 4.2%
Renal Failure 4.2%
Tooth Disorder 4.2%
Herpes Zoster 3.2%
Hypertension 3.2%
Oedema 3.2%
Throat Cancer 3.2%
Thrombocytopenia 3.2%
Urinary Tract Infection 3.2%
Deafness 2.1%
Haemolysis 2.1%
Hepatitis B 2.1%

Drug Data